Evoke Pharma Stock Today
| EVOK Stock | USD 5.37 0.03 0.56% |
PerformanceModest
| Odds Of DistressHigh
|
Evoke Pharma is selling for 5.37 as of the 17th of February 2025. This is a 0.56 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 4.92. Evoke Pharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 28th of February 2023 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of September 2013 | Category Healthcare | Classification Health Care |
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. The company has 1.49 M outstanding shares of which 41.71 K shares are currently shorted by private and institutional investors with about 3.02 trading days to cover. More on Evoke Pharma
Moving against Evoke Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Evoke Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO CoFounder | David RPh | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEvoke Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Evoke Pharma's financial leverage. It provides some insight into what part of Evoke Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Evoke Pharma (EVOK) is traded on NASDAQ Exchange in USA. It is located in 420 Stevens Avenue, Solana Beach, CA, United States, 92075 and employs 4 people. Evoke Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.98 M. Evoke Pharma conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.49 M outstanding shares of which 41.71 K shares are currently shorted by private and institutional investors with about 3.02 trading days to cover.
Evoke Pharma currently holds about 13.45 M in cash with (4.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02.
Check Evoke Pharma Probability Of Bankruptcy
Ownership AllocationEvoke Pharma shows 4.58 percent of its outstanding shares held by insiders and 14.7 percent owned by other corporate entities.
Check Evoke Ownership Details
Evoke Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bleichroeder Lp | 2024-09-30 | 68.8 K | |
| Nantahala Capital Management, Llc | 2024-09-30 | 56.2 K | |
| Corsair Capital Management Llc | 2024-09-30 | 11.7 K | |
| Tower Research Capital Llc | 2024-09-30 | 816 | |
| Blackrock Inc | 2024-09-30 | 122 | |
| Ubs Group Ag | 2024-09-30 | 90.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 31.0 | |
| Bank Of America Corp | 2024-09-30 | 25.0 | |
| Goss Wealth Management Llc | 2024-09-30 | 17.0 | |
| Citigroup Inc | 2024-09-30 | 4.0 | |
| Aigh Capital Management, Llc | 2024-12-31 | 0.0 |
Evoke Pharma Historical Income Statement
Evoke Stock Against Markets
Evoke Pharma Corporate Management
| Mark CPA | Chief Officer | Profile | |
| DMD MD | Chief Officer | Profile | |
| Christopher Quesenberry | Chief Gimoti | Profile | |
| Marilyn Carlson | Chief Medical Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share | Quarterly Revenue Growth 0.698 | Return On Assets | Return On Equity |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.